Treatment Goals for LDL-c to Reduce Cardiovascular Risk in Individuals with High and Very High Cardiovascular Disease Risk*

Treatment algorithm for pharmacological low-density lipoprotein cholesterol lowering*

Adapted from: 2019 ESC/EAS Guidelines for the management of dyslipidaemia: lipid modification to reduce cardiovascular risk. European Heart Journal, 2020, 41:111-188.

Abbreviations:
ASCVD = atherosclerotic cardiovascular disease;
BP = blood pressure;
CKD = chronic kidney disease;
CVD = cardiovascular disease;
DM = diabetes mellitus;
eGFR = estimated glomerular filtration rate;
LDL-C = low-density lipoprotein cholesterol;
PCSK9 = proprotein convertase subtilisin/kexin type 9;
SCORE = Systematic Coronary Risk Estimation;
T1DM = type 1 DM;
T2DM = type 2 DM;
TC = total cholesterol

SCORE2 and SCORE2-OP Cardiovascular disease risk estimation stratified by age*
CV risk estimation	< 50y	50 - 69y	> 70y
Low / moderate	< 2.5%	< 5%	< 7.5%
High	2.5 - < 7.5%	5 - < 10%	7.5 - < 15%
Very high	> 7.5%	> 10%	> 15%

* For the cardiovascular risk definitions, please refer to the 2019 ESC/EAS Guidelines for the management of dyslipidaemia: lipid modification to reduce cardiovascular risk.